Qiancheng Xu1, Qian Yan1, Shanghua Chen1. 1. Department of Critical Care Medicine, Wuhu No. 2 People's Hospital, Wannan Medical College, Wuhu 241000, China.
Abstract
BACKGROUND: Ulinastatin has anti-inflammatory properties and could potentially benefit critically ill septic patients. Nevertheless, clinical studies have yielded conflicting results. The present study examined the efficacy of ulinastatin in intensive care unit (ICU) patients with sepsis and/or septic shock. METHODS: All septic patients admitted to the ICU of Wuhu No. 2 People's Hospital between 2014 and 2017 were screened for potential eligibility for this retrospective study. The primary outcome was 28-day mortality, and its correlation with ulinastatin was assessed using multiple logistic regression models. RESULTS: The study included 263 patients, with an overall 28-day mortality of 38%. Patients receiving ulinastatin showed significantly lower mortality than the control patients (31% vs. 55%; P<0.001). Ulinastatin use was associated with significantly reduced risk of death (OR: 0.317, 95% CI: 0.158-0.621; P=0.001) after adjustment for age, Sequential Organ Failure Assessment score, vasopressor use, and patient type as determined with a multivariable regression model. CONCLUSIONS: Treatment with ulinastatin was associated with a decrease in 28-day mortality in critically ill septic patients.
BACKGROUND: Ulinastatin has anti-inflammatory properties and could potentially benefit critically ill septic patients. Nevertheless, clinical studies have yielded conflicting results. The present study examined the efficacy of ulinastatin in intensive care unit (ICU) patients with sepsis and/or septic shock. METHODS: All septic patients admitted to the ICU of Wuhu No. 2 People's Hospital between 2014 and 2017 were screened for potential eligibility for this retrospective study. The primary outcome was 28-day mortality, and its correlation with ulinastatin was assessed using multiple logistic regression models. RESULTS: The study included 263 patients, with an overall 28-day mortality of 38%. Patients receiving ulinastatin showed significantly lower mortality than the control patients (31% vs. 55%; P<0.001). Ulinastatin use was associated with significantly reduced risk of death (OR: 0.317, 95% CI: 0.158-0.621; P=0.001) after adjustment for age, Sequential Organ Failure Assessment score, vasopressor use, and patient type as determined with a multivariable regression model. CONCLUSIONS: Treatment with ulinastatin was associated with a decrease in 28-day mortality in critically ill septic patients.
Authors: Sandra L Peake; Anthony Delaney; Michael Bailey; Rinaldo Bellomo; Peter A Cameron; D James Cooper; Alisa M Higgins; Anna Holdgate; Belinda D Howe; Steven A R Webb; Patricia Williams Journal: N Engl J Med Date: 2014-10-01 Impact factor: 91.245
Authors: D C Angus; A E Barnato; D Bell; R Bellomo; C-R Chong; T J Coats; A Davies; A Delaney; D A Harrison; A Holdgate; B Howe; D T Huang; T Iwashyna; J A Kellum; S L Peake; F Pike; M C Reade; K M Rowan; M Singer; S A R Webb; L A Weissfeld; D M Yealy; J D Young Journal: Intensive Care Med Date: 2015-05-08 Impact factor: 17.440
Authors: Dilip R Karnad; Rakesh Bhadade; Pradeep K Verma; Nivedita D Moulick; Mradul K Daga; Neelima D Chafekar; Shivakumar Iyer Journal: Intensive Care Med Date: 2014-04-16 Impact factor: 17.440